Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM
6.1. Overview
6.2. Eye Drops
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.3. Eye Ointments
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.4. Eye Solutions
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.5. Eye Gels
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.6. Eye Capsules & Tablets
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
6.7. Others
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7. GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG CLASS
7.1. Overview
7.2. Antibiotics
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.3. Nonsteroidal Drugs
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.4. Anti-allergy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.5. Anti-Inflammatory
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.6. Anti-Glaucoma
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
7.7. Others
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8. GLOBAL OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE
8.1. Overview
8.2. Prescription Drugs
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
8.3. OTC Drugs
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
9. GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION
9.1. Overview
9.2. Allergy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
9.3. Dry Eye
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
9.4. Glaucoma
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
9.5. Others
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
10. GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. Italy
10.3.1.4. Spain
10.3.1.5. UK
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPANY LANDSCAPE
11.1.1. Overview
11.1.2. Competitive Analysis
12. COMPANY PROFILE
12.1. Novartis AG
12.1.1. Overview
12.1.2. Product Overview
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Allergan Plc
12.2.1. Overview
12.2.2. Product Overview
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. F. Hoffmann-La Roche AG
12.3.1. Overview
12.3.2. Product Overview
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Bausch Health Companies Inc
12.4.1. Overview
12.4.2. Product Overview
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Pfizer Inc.
12.5.1. Overview
12.5.2. Product Overview
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Bayer AG
12.6.1. Overview
12.6.2. Product Overview
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Merck & Co., Inc.
12.7.1. Overview
12.7.2. Product Overview
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Regeneron Pharmaceuticals, Inc.
12.8.1. Overview
12.8.2. Product Overview
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Aerie Pharmaceuticals, Inc.
12.9.1. Overview
12.9.2. Product Overview
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Santen Pharmaceutical Co., Ltd
12.10.1. Overview
12.10.2. Product Overview
12.10.3. Financial Overview
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Others
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL OPHTHALMIC DRUGS MARKET SYNOPSIS, 2020–2027
TABLE 2 GLOBAL OPHTHALMIC DRUGS MARKET ESTIMATES AND FORECAST, 2020–2027 (USD MILLION)
TABLE 3 GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 5 GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 6 GLOBAL OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 7 GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 8 NORTH AMERICA: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 10 NORTH AMERICA: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 11 NORTH AMERICA: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 12 US: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 13 US: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 14 US: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 15 US: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 16 CANADA: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 17 CANADA: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 18 CANADA: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 19 CANADA: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 20 LATIN AMERICA: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 21 LATIN AMERICA: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 22 LATIN AMERICA: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 23 LATIN AMERICA: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 25 EUROPE: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 27 EUROPE: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 28 WESTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 29 WESTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 30 WESTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 31 WESTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 32 EASTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 33 EASTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 34 EASTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 35 EASTERN EUROPE: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA: OPHTHALMIC DRUGS MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2020–2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: OPHTHALMIC DRUGS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: OPHTHALMIC DRUGS MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL OPHTHALMIC DRUGS MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL OPHTHALMIC DRUGS MARKET
FIGURE 4 GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY DRUG CLASS, 2020 (%)
FIGURE 5 GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY DOSAGE FORM, 2020 (%)
FIGURE 6 GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY INDICATION, 2020 (%)
FIGURE 7 GLOBAL OPHTHALMIC DRUGS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: OPHTHALMIC DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: OPHTHALMIC DRUGS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: OPHTHALMIC DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: OPHTHALMIC DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: OPHTHALMIC DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL OPHTHALMIC DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 NOVARTIS AG: KEY FINANCIALS
FIGURE 15 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 16 NOVARTIS AG: REGIONAL REVENUE
FIGURE 17 ALLERGAN PLC: KEY FINANCIALS
FIGURE 18 ALLERGAN PLC: SEGMENTAL REVENUE
FIGURE 19 ALLERGAN PLC: REGIONAL REVENUE
FIGURE 20 F. HOFFMANN-LA ROCHE AG: KEY FINANCIALS
FIGURE 21 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE
FIGURE 22 F. HOFFMANN-LA ROCHE AG: REGIONAL REVENUE
FIGURE 23 BAUSCH HEALTH COMPANIES INC: KEY FINANCIALS
FIGURE 24 BAUSCH HEALTH COMPANIES INC: SEGMENTAL REVENUE
FIGURE 25 BAUSCH HEALTH COMPANIES INC: REGIONAL REVENUE
FIGURE 26 PFIZER INC: KEY FINANCIALS
FIGURE 27 PFIZER INC: SEGMENTAL REVENUE
FIGURE 28 PFIZER INC: REGIONAL REVENUE
FIGURE 29 BAYER AG: KEY FINANCIALS
FIGURE 30 BAYER AG: SEGMENTAL REVENUE
FIGURE 31 BAYER AG: REGIONAL REVENUE
FIGURE 32 MERCK & CO., INC.: KEY FINANCIALS
FIGURE 33 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 34 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 35 REGENERON PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 36 REGENERON PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 37 REGENERON PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 38 AERIE PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 39 AERIE PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 40 AERIE PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 41 SANTEN PHARMACEUTICAL CO., LTD: KEY FINANCIALS
FIGURE 42 SANTEN PHARMACEUTICAL CO., LTD: SEGMENTAL REVENUE
FIGURE 43 SANTEN PHARMACEUTICAL CO., LTD: REGIONAL REVENUE
